|>> || >>148704 |
Eventually, yes absolutely all the ones that come to mind will 100% be banned or otherwise scheduled. It's a 99% certainty. The only debate is when and how long until specific substances are banned. Kratom may be an outlier in this assumption because its both quasi-medically useful, isn't really relatively reabusable, has a cult following, and has a zillion people as screaming living testimonials about how it saved their lives. However, even there, once specific alkaloids in kratom are finally approved through Phase 2 and 3 trials and FDA approved, expect the plant leaf to become Schedule 3, 4, or 5 (I suspect S3) at some point, if not full pants on head silly mode with entire plain leaf and extracts pushed to S1 while the specific patented kratom chems become S2, 3, or 4 (I suspect S3 for mitragynine and S2 for 7-HMG, but who knows). I highly suspect any and all FDA approved kratom analogues will be either S2 or S3 even without the typical opi OD potential, by virtue of not wanting to have then overprescribed.
Stuff like tiantepine, phenibut, etc. will be scheduled eventually, whether S1 or S2-5. If not S1, it would make sense to make phenibut S4 or S5 mostly S5 (like pregabalin), and tiantepine S2/S3 due to opioid effects.
What really has me concerned is the long term modification of the Drug Analogue laws by way of adding S4 and S5 drugs to the list. Currently, analogues of S4 and S5 are generally legal if they're not for human consumption. I dont know if phenibut would technically be considered an analogue of pregabalin, but they're both gabapentinoids. That's how they could get phenibut and virtually all RC benzos in one swoop.
They've already made unwashed poppy seeds illegal, at least on paper. Etizolam and a few others I cant recall were suggested to the UN recently; Hamilton Morris tweeted about it. O-DSMT will be scheduled soon enough if it isn't already technically an analogue of a S2 or S3 by way of a patent on either O-DSMT or a related analogue already going through Phase 1/2 trials, and IIRC at phase 3 is when the scheduling begins.
So yeah, this stuff is coming. Adding S4 and S5 to the analogue Act, and federally scheduling gabapentin to S5, will end RC benzos on the clear net. As the UN members slowly implement the mutual agreements, in theory China/India will tighten up RC benzos and precursors.
But don't worry. There's SO many RC avenues and haven't even been tapped into at all, like methadone analogues, thebaine-variant analogues, and so so much more. They can make some that are so chemically speaking unrelated to the Schedule original drug that it will be a valid legal defense to say it's not an analogue.
These are interesting times.